vonoprazan/amoxicillin

{{Infobox drug

| type = combo

| image = Vonoprazan and amoxicillin.svg

| component1 = Vonoprazan

| class1 = Potassium-competitive acid blocker

| component2 = Amoxicillin

| class2 = Beta-lactam antibiotic

| tradename = Voquezna Dual Pak

| Drugs.com =

| MedlinePlus =

| DailyMedID = Voquezna

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration = By mouth

| ATCvet =

| ATC_prefix = A02

| ATC_suffix = BD17

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit | website=DailyMed | date=21 June 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 | access-date=3 July 2022 | archive-date=3 July 2022 | archive-url=https://web.archive.org/web/20220703054730/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86 | url-status=live }}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| synonyms =

}}

Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection. It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic. It is taken by mouth.

The co-packaged medication was approved for medical use in the United States in May 2022.{{cite press release | title=Phathom Pharmaceuticals Announces FDA Approval of Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | publisher=Phathom Pharmaceuticals | via=GlobeNewswire | date=3 May 2022 | url=https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html | access-date=9 May 2022 | archive-date=10 May 2022 | archive-url=https://web.archive.org/web/20220510034341/https://www.globenewswire.com/en/news-release/2022/05/03/2435147/0/en/Phathom-Pharmaceuticals-Announces-FDA-Approval-of-VOQUEZNA-TRIPLE-PAK-vonoprazan-amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.html | url-status=live }}{{cite web|url=https://www.drugs.com/history/voquezna-dual-pak.html|title=Voquezna Dual Pak (amoxicillin and vonoprazan) FDA Approval History|website=Drugs.com|access-date=16 May 2022|archive-date=16 May 2022|archive-url=https://web.archive.org/web/20220516040849/https://www.drugs.com/history/voquezna-dual-pak.html|url-status=live}}{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf |title=FDA NDA approval |website=U.S. Food and Drug Administration (FDA) |access-date=12 May 2022 |archive-date=12 May 2022 |archive-url=https://web.archive.org/web/20220512000404/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000,%20215153Orig1s000ltr.pdf |url-status=dead }}

Medical uses

Vonoprazan/amoxicillin is indicated for the treatment of H. pylori infection in adults.{{cite web | title=Voquezna Dual Pak (vonoprazan/amoxicillin) monograph | website=Medscape | date=5 May 2022 | url=https://reference.medscape.com/drug/voquezna-dual-pak-vonoprazan-amoxicillin-4000290 | access-date=11 May 2022 | archive-date=11 May 2022 | archive-url=https://web.archive.org/web/20220511232203/https://reference.medscape.com/drug/voquezna-dual-pak-vonoprazan-amoxicillin-4000290 | url-status=live }}

Research

The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment of H. pylori infection{{cite journal | vauthors = Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K | title = Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan | journal = Gut | volume = 69 | issue = 6 | pages = 1019–1026 | date = June 2020 | pmid = 31915235 | pmc = 7282559 | doi = 10.1136/gutjnl-2019-319954 }} and also compared with the triple therapy of using vonoprazan, amoxicillin, and clarithromycin for the eradication of H. pylori infection.{{cite journal | vauthors = Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K | title = Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori | journal = Digestion | volume = 101 | issue = 6 | pages = 743–751 | date = November 2020 | pmid = 31434101 | doi = 10.1159/000502287 | s2cid = 201277349 }} Both treatments have been found to be effective. {{As of|2024|post=,}} evidence indicates that vonoprazan/amoxicillin therapy has similar efficacy to bismuth-containing quadruple therapies in eliminating H. pylori.{{cite journal |vauthors=Pai L, Patil S, Liu S, Wen F |title=A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance |journal=Front Cell Infect Microbiol |volume=13 |issue= |pages=1327069 |date=2023 |pmid=38188636 |pmc=10770264 |doi=10.3389/fcimb.2023.1327069 |doi-access=free |url=}}

References

Category:Combination antibiotics

Category:Drugs acting on the gastrointestinal system and metabolism

Category:Proton-pump inhibitors